Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads

Scotté, Florian; Rey, Jean‐Baptiste; Launay-Vacher, Vincent

doi:10.1007/s00520-012-1590-9

Cited by 30 publications

(25 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…48 Cancer and Other Indications VTE is a common cause of morbidity and mortality in patients with cancer, with an estimated incidence between 4 and 20%. 49 Patients at greatest VTE risk are those who are hospitalized, undergoing active chemotherapy, or have metastatic disease. 50 Additional risk factors for VTE include treatment with certain chemotherapy regimens, the presence of certain tumors, and insertion of indwelling central venous catheters.…”

Section: Renal Failurementioning

confidence: 99%

“…50 Additional risk factors for VTE include treatment with certain chemotherapy regimens, the presence of certain tumors, and insertion of indwelling central venous catheters. 49 The CLOT study compared warfarin and dalteparin for prevention of symptomatic, recurrent VTE in patients with active cancer and found that dalteparin was the more effective treatment, with recurrence in 8.0 versus 15.8% of patients. 51 Current guidelines recommend treating patients with advanced or metastatic cancer with LMWH monotherapy for the first 6 months after VTE.…”

Section: Renal Failurementioning

confidence: 99%

See 1 more Smart Citation

Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux

Babin

Traylor

Witt

2016

Semin Thromb Hemost

View full text Add to dashboard Cite

Compared with older agents, low-molecular-weight heparins (LMWH) and fondaparinux offer improved bioavailability and more predictable, dose-independent clearance. While routine monitoring of coagulation parameters is not usually necessary with these agents, certain populations (including pregnant patients, children, obese patients, and patients with renal impairment) may benefit from the monitoring of anti-factor Xa activity, thromboelastography, or other coagulation assays to help guide therapy. The chromogenic anti-factor Xa assay is currently the gold standard for monitoring LMWH and fondaparinux therapy. Thromboelastography has been used to monitor LMWH therapy in special situations but is not needed for routine use.

show abstract

Section: Renal Failurementioning

confidence: 99%

Section: Renal Failurementioning

confidence: 99%

Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux

Babin

Traylor

Witt

2016

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Venous thromboembolism (VTE), and pulmonary embolism (PE) in particular, are increasingly frequent complications in patients with malignancy, representing the second most common cause of death, following cancer itself 2,3. Despite this fact, the reported frequency of VTE in cancer patients is probably underestimated, given that autopsy rates of VTE can be as high as 50% compared with clinical rates of 4%–20% 4…”

Section: Cancer and Thrombosismentioning

confidence: 99%

“…This is not a minor feature; indeed, abnormal renal function is a common condition in patients with malignancy 37. According to the Renal Insufficiency and Anticancer Medications study group,3 50%–60% of patients with solid tumors, including the most common cancers including lung, breast, and prostate cancer, have abnormal renal function or renal insufficiency – a fact that may prove crucial when choosing the most appropriate LMHW for an individual patient 3…”

Section: Treatment Of Thrombosis In Cancer Patientsmentioning

confidence: 99%

What is the Best Treatment for a Cancer Patient with Thrombosis?

Barbosa

2014

Clin Med Insights Oncol

View full text Add to dashboard Cite

The relationship between venous thromboembolism and cancer has been known for many years, and there is solid scientific evidence addressing the adequate treatment of this condition in oncology patients. However, established prescribing habits, individual patient challenges, and uncertainty concerning treatment justifies poor adherence to published guidelines. This paper reviews venous thromboembolism treatment while focusing on vitamin K antagonists, low-molecular-weight heparins, and novel oral anticoagulants, namely in terms of their efficacy and limitations.

show abstract

“…Enoxaparin is a low-molecular-weight heparin, belonging to the category of organic acid compounds known as mucopolysaccharides, affecting thrombosis and angiogenesis in various cancers. Enoxaparin has an inhibitory effect on venous thrombosis, pulmonary embolism, acute coronary syndrome, thrombosis and angiogenesis in various cancers [1,2]. Angiogenesis in cancer is the process of new blood vessel formation around the tumor as endothelial cells multiply.…”

Section: Introductionmentioning

confidence: 99%

Effects of Enoxaparin Emulsion on Dimethylbenzanthracene-induced Breast Cancer in Female Rats

Bolandpayeh

Hassanpour-Ezzati

Mousavi

2018

RMM

View full text Add to dashboard Cite

Introduction: Enoxaparin is an anticoagulant medication. Anticoagulation inhibits tumor cell-mediated release of angiogenic proteins and diminishes angiogenic response. Angiogenesis is an important event in various cancers such as breast cancer. Angiogenesis provide oxygen and nutrients to tumor cells and causes tumor progression. The aim of the present study was to evaluate the anti-angiogenesis effect of an enoxaparin cream on breast cancer induced by dimethylbenzanthracene in rats. Methods: In this experimental in vivo study, 50 Wistar female rats were divided into negative control (vehicle), positive control (cream base), and 3 groups with enoxaparin treatment (40, 60, and 80 mg/ml). After one month of treatment along with breast cancer induction by dimethylbenzanthracene, breast tissue samples were isolated and stained with hematoxylin-eosin, and tumor growth suppression rate was calculated. Tumor size (length and width) was measured using a clipper, and the tumor volume was calculated using the following formula: V = (L × W × W)/2, where V is tumor volume, W is tumor width, L is tumor length. The data were analyzed using one-way ANOVA and Tukey’s post hoc test. Results: Tumor suppression was significantly increased in enoxaparin treatment groups compared to the positive control group (40 mg/ml of enoxaparin treated versus positive control group; P = 0.017, 60 mg/ml of enoxaparin treated versus positive control; P = 0.015, 40 mg/ml of enoxaparin treated versus positive control; P = 0.009, 60 mg/ml of enoxaparin treated versus 40 mg/ml of enoxaparin treated; P = 0.019, and 80 mg/ml of enoxaparin treated versus 40 mg/ml of enoxaparin treated; P = 0.011 in a dose-dependent manner. Conclusion: Enoxaparin inhibits breast cancer in a dose-dependent manner. The application of enoxaparin cream in patients with breast cancer may considerably reduce tumor growth.

show abstract

Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads

Abstract: VTE is the second most common cause of death in cancer patients. Renal insufficiency is present in 50-60 % of cancer patients. Data from renal patients suggest that tinzaparin may be safe and effective for VTE treatment and prevention in cancer patients with renal failure.

Cited by 30 publications

References 60 publications

Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux

Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux

What is the Best Treatment for a Cancer Patient with Thrombosis?

Effects of Enoxaparin Emulsion on Dimethylbenzanthracene-induced Breast Cancer in Female Rats

Contact Info

Product

Resources

About